Use of guanfacine in the treatment of behavioral disorders

• US 5,854,290 A
• Filed: 09/21/1995
• Issued: 12/29/1998
• Est. Priority Date: 09/21/1995
• Status: Expired due to Term

• Current Assignee: Amy FT Arnsten (Amy F.T. Arnsten PHD), Patricia Goldman-Rakic
• Original Assignee: Amy FT Arnsten (Amy F.T. Arnsten PHD), Patricia Goldman-Rakic, Robert H. Hunt
• Inventors: Hunt, Robert H., Goldman-Rakic, Patricia S., Arnsten, Amy F. T.
• Primary Examiner(s): Jarvis, William R. A.
• Application Number:
  US08/531,643
• Time in Patent Office: 1,195 Days
• Field of Search: 514/634, 514/617
• US Class Current: 514/617
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/4164 1,3-Diazoles

Abstract

Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette'"'"'s Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.

Claims

1. A method of treating a behavioral disinhibition in a primate without inducing excessive sedation, comprising

administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight.

2. The method of claim 1, comprising the additional step of readministering the dose at an interval required to obtain a desired level and duration of behavioral inhibition.

3. The method of claim 1, wherein the primate is a rhesus monkey.

4. The method of claim 1, wherein the primate is a human.

5. The method of claim 4, wherein the dose ranges between about 0.03 mg/kg of body weight and about 0.25 mg/kg of body weight.

6. The method of claim 1, wherein the behavioral disinhibition is one of Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional-Defiant Disorder, Tourette'"'"'s Syndrome, Lesch-Nyhan Syndrome, Post-Traumatic Stress Disorder and dementia.

7. A method of inhibiting a disinhibitory behavior in a primate without inducing excessive sedation, comprising:

administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight.

8. The method of claim 7, comprising the additional step of readministering the dose at an interval required to obtain a desired level and duration of behavioral inhibition.

9. The method of claim 7, wherein the primate is a rhesus monkey.

10. The method of claim 7, wherein the primate is a human.

11. The method of claim 10, wherein the dose ranges between about 0.03 mg/kg of body weight and about 0.25 mg/kg of body weight.

12. The method of claim 7, wherein the behavior is one of hyperactivity, agitation, impulsivity, aggression, inattention, distractibility, disorganization, uncontrolled movements, and self-mutilation.